Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,049 across all filing types
Latest filing 2020-12-31 Regulatory Filings
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Glenmark Pharmaceuticals has received final and tentative approvals from the U.S. FDA for certain pharmaceutical products. It is addressed to stock exchanges and includes a media release attachment. The content focuses on regulatory approvals and product pipeline updates rather than financial results or detailed financial statements. The document length is 4808 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication of financial data, management discussion, or detailed reporting. Therefore, this document is best classified as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance-related disclosures that do not fit other specific categories.
2020-12-31 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a new pharmaceutical product by Glenmark Pharmaceuticals. It is addressed to stock exchanges and includes a media release about the product launch, pricing, and market information. There is no financial data, regulatory filing, or report content such as annual or quarterly financial statements. The document is a corporate announcement related to product launch and marketing, not a financial or regulatory report. Therefore, it does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. It is best classified as a general Regulatory Filing (RNS) since it is a regulatory announcement to stock exchanges but not a financial report or other specific filing type.
2020-12-29 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release announcing an exclusive licensing agreement between Glenmark Pharmaceuticals and Menarini for commercialization of a pharmaceutical product in Europe. It is addressed to stock exchanges and includes a request to take the announcement on record. The content focuses on a business partnership and licensing deal, not on financial results, regulatory filings, or management changes. There are no financial statements, earnings data, or regulatory certifications. The document is a corporate announcement about a commercial agreement, which fits best under Capital/Financing Update (CAP) as it relates to licensing and commercial arrangements impacting company capital and business operations.
2020-12-23 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Glenmark Pharmaceuticals has received tentative approval from the U.S. FDA for a generic drug. It is addressed to stock exchanges and includes a media release. The content is a corporate announcement about regulatory approval and product pipeline status, not a financial report, earnings release, or management discussion. The document length is 3416 characters, which is relatively short and consistent with a press release or announcement. There is no financial data, no meeting materials, no voting results, no legal proceedings, no share transactions, and no detailed financial or governance information. Therefore, the document best fits the category of a Regulatory Filing (RNS), which is the fallback for miscellaneous regulatory announcements and corporate disclosures that do not fit other categories.
2020-12-21 English
Updates
Regulatory Filings
2020-12-11 English
Updates
Capital/Financing Update Classification · 95% confidence The document is an official announcement addressed to stock exchanges (BSE and NSE) regarding the redemption of a portion of the company's senior notes (debt securities). It references compliance with the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements (LODR) regulations. The content focuses on a capital structure event — specifically, the redemption of debt securities — and does not contain financial statements or detailed financial performance data. The document length is short (3016 characters) and is clearly an update on financing activity. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2020-12-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.